Introduction
Recent evidence suggests that the HIV epidemic is in part being driven by drug abuse. This group of individuals is the fastest growing population with HIV infection in the United States and Western European countries, yet, very little is known about the potential interaction of these drugs with HIV infection in the genesis of cerebral dysfunction. The observation of an increased frequency of HIV encephalitis at autopsy among drug abusers (Bell et a l, 1998) suggests that a relationship between these drugs of abuse and HIV infection exists. We report the constellation of HIV dementia, seizures and an unusual movement disorder that developed in association with the non-parenteral use of methamphetamine and cocaine. The movement disorder but not the dementia responded to treatment with L-DOPA and anticholinergic therapy. We discuss possible pathophysiological mechanisms that might contribute to the interactions of drugs of abuse and HIV infection on cerebral function.
Results

Ca se re p o rt
We report ED, a 44 year old HIV seropositive man with a 10 year history of recreational use (every weekend) of methamphetamine (oral) and cocaine (intra-nasal). HIV seropositivity was initially demonstrated in March 1995, when he developed pneumoc ystis pneumonia. CD4 cell count at that time was 0 cells/l l of blood. In August 1998, after 3 years of highly active antiretroviral therapy he developed generalized seizures. MRI scan revealed cerebral and basal ganglia atrophy with diffuse white matter high signal intensity lesions on T2 weighted images (Figure 1 ). EEG showed left temporal spikes and rhythmic delta waves. CS F showed 20 white blood cells/l l, (all mononuclear), 2 red blood cells/l l, protein of 55 mg/dl, glucose of 50 mg/dl. The CS F IgG index was elevated at 2.56 (normal 0.28 ± 0.66) and oligoclonal bands were present but myelin basic protein was normal at 0.2 (range 0 ± 2.3 ng/ml). After August 1998, his CD4 cell count ranged from 50 ± 200 cells/mm 3 of blood and HIV load ranged from 300 ± 1000 RNA copies/ ml of plasma. He scored 10/16 on the HIV Dementia Scale (Power e t a l, 1995) and 2 on the Memorial Sloan Kettering Scale (Price and Brew, 1988) suggestive of a moderate HIV dementia. Repeat neurophyschological evaluations showed progressive impairment with severely delayed recall and moderate abnormalities in learning, attention and concentration. His seizures were controlled on phenytoin and gabapentin. Drug levels for phenytoin remained in the therapeutic range (10 ± 20 mg/ L) for the duration of follow-up, although free levels were not measured.
The patient stopped cocaine use after the onset of the ®rst seizure and methamphetamine use 3 months later. In April 1999, he developed a painful focal dystonia with¯exion at the right wrist, spooning of the ®ngers most prominent on extension of the hands, choreoathetosis of the ®ngers, coarse resting tremor of the hands (greater on the left) with cogwheel rigidity and postural instability. There was no history of exposure to neuroleptics. This patient was extensively investigated for all other causes of dementia and movement disorders including thyroid func tion tests, vitamin B12, folate levels, serum copper and ceruloplasmin levels, RPR, a complete vasculitis work up, blood smear for acanthosis, and complete blood chemistry with liver function tests. All were negative or normal.
Analysis of the time course of post-contrast enhancement in the striatum 3 months prior to and 3 weeks following the onset of motor symptoms ( Figure 2 ) revealed that FE30 which was elevated (0.018) relative to non-demented HIV infec ted volunteers (FE30=0.002 6 0.001) when the patient was ®rst studied, had become markedly elevated (FE30=0.033) when the patient was restudied~4 months later following the onset of motor symptoms. FEmax data were not available when the patient was ®rst studied, due to motion artifacts in the early part of the study. However, when the patient was restudied following the onset of motor symptoms, FEmax was not signi®cantly different from that found in non-demented HIV infected volunteers. These results suggest progressive decline in BBB integrity in the basal ganglia accompanied the onset of motor symptoms, but minimal alteration in basal ganglia vascularity. Treatment of the dystonia associated pain with a variety of nonnarcotic and narcotic analgesics was ineffec tive. However, the movement disorder and the pain responded dramatically to treatment with Sinemet (carbidopa/L-dopa) 10/100, three times daily and artane (6 mg/day). The pain resolved within 1 week of treatment and the involuntary movements improved within 2 ± 3 weeks. There was a partial resolution of the postural instability but no effec t on his cognitive impairment.
Discussion
This case report illustrates several important features. There was a progressive decline of neuropsychological functioning despite aggressive antiretroviral therapy and control of viral load. This was associated with cerebral and basal ganglia atrophy, diffuse white matter changes, a left temporal seizure focus and mild CSF pleocytosis with intrathecal synthesis of immunoglobulins. These observations are consistent with a rapidly progressive HIV dementia that is usually associated with poor prognosis (Bouwman e t a l, 1998). Antiretroviral therapy has been shown to reverse the neropsychological manifestations of HIV dementia in some patients (Gendelman et a l, 1998) and has had a positive impact on the natural history of HIV dementia (Price e t a l, 1999; Sacktor e t a l, 1999). However, as illustrated by this case report, severe and progressive HIV dementia may occur despite the use of highly potent antiretroviral therapy. Antiretroviral drugs, in general, poorly penetrate the blood brain barrier (Aweeka e t a l, 1999), hence, it is possible that once HIV-infec ted or activated macrophages enter the brain, antiretroviral therapy may not have a major impact on the neuropathogenesis of HIV infection. The role of drug abuse in this apparent failure of antiretroviral therapy needs further study.
S tudies addressing the frequenc y of HIV dementia in drug abusers have produced variable results. While Italian investigators (Grassi e t a l, 1997) found a profound negative in¯uenc e of drug abuse on cognitive function among HIV-infec ted persons, the Johns Hopkins group did not report a differenc e in the incidence of dementia in HIV-infec ted drug users (Concha e t a l, 1992 (Concha e t a l, , 1997 ; S elnes e t a l., 1997). A subsequent study showed that a history of injection drug use and presentation with prominent psychomotor slowing was associated with more rapid neurologic progression and that these patients had more abundant macrophage activation within the CNS (Bouwman e t a l, 1998) . Pathological studies from a cohort in S cotland (Bell e t a l, 1998) revealed that 56% of the brains of HIV-infec ted drug users had features of HIV enc ephalitis evidenc ed by the presenc e of HIV p24 and multinucleated giant cells in comparison to only 17% of homosexual HIV-infec ted men coming to autopsy. These studies support the notion that, although drug abuse may not have a dramatic effec t on the incidence of dementia, once HIV neurocognitive impairment does occur, drug abuse may cause or initiate a rapid and severe decline in cerebral func tion as seen in this case report.
The basal ganglia face the major brunt of HIV infection in the brain. Multinucleated giant cells, microglial nodules, and HIV-infec ted microglial cells and in®ltrating macrophages are most prominent in the basal ganglia, compared to other regions within the brain (Navia e t a l, 1986 ). Viral load is also maximal in this region (Fujimura e t a l, 1997). Signi®cant neuronal cell loss, is also noted in the pars compacta of the substantia nigra (Reyes e t a l, 1991). Low levels of dopamine are also present in the caudate nucleus of patients with AIDS (Sardar e t a l, 1996). CSF homovanillic acid levels are diminished in patients with AIDS and more severely so in patients with AIDS dementia (Berger e 
t a l, 1994; Larsson e t a l, 1991). HIV neurotoxic proteins Tat and gp120 can both be detected in the basal ganglia of patients with HIV encephalitis (Hofman e t a l, 1994; Kruman e t a l, 1999; Nath e t a l, 2000).
Injection of Tat into the lateral ventricle in rats causes apoptosis of stiatal neurons (Jones e t a l, 1998). Injection of Tat into the striatum, leads to loss of striatal N-acetyl aspartate peak by nuclear magnetic resonance spectroscopy (Berger and Nath, 1997) and loss of niagrostiatal ®bers (Hayman e t a l, 1993) . Consistent with these pathological observations, patients with HIV infection may develop a variety of movement disorders (reviewed in Berger and Nath, 1997) . To date, however, the combination of motor abnormalities manifesting as focal dystonia, choreoathetosis and resting tremor abnormalities in a single patient have not been reported to the best of our knowledge. This constellation of signs suggests the possibility that the combination of drug abuse and HIV infection may have contributed to the aggressive and unusual course of HIV dementia with prominent effects on the basal ganglia.
Drugs of abuse such as cocaine and methamphetamine may interact with HIV in several different ways to accelerate the neurological complications of HIV infection. Cocaine has been shown to cause a breakdown of the blood brain barrier resulting in increased traf®cking of monocytes and virus into the brain (Fiala e t a l, 1998) . MRI studies in the present case report also showed a signi®cant break down of the blood brain barrier in the striatum. These drugs may also have direct effec ts on neurons. Amphetamines potentiate the release of dopamine into the synaptic cleft. Cocaine is a nonselec tive inhibitor of dopamine uptake, acting through inhibition of the dopamine transporter. Inhibition of the transporter results in a rapid increase of dopamine in the synaptic cleft, which has been hypothesized to underlie the euphoric rush' that accompanies cocaine abuse. Chronic amphetamine and cocaine use, thus, deplete the dopamine pools and are associated with reduced levels of striatal dopamine and the dopaminergic transporter in humans (Wilson e t a l, 1996a, b) . A single dosing of methamphetamine may be suf®-cient to cause dopamine neurotoxicity as evidenced by the loss of dopamine transporter detection by positron emission tomography (Villemagne e t a l, 1998) . Recent studies show that chronic methamphamine use is associated with neurodegeneration as determined by MRS studies. (Ernst e t a l, 2000) . We have also shown that methamphetamine and cocaine may synergize to cause neurotoxicity (Nath e t a l, in press).
Importantly, this patient showed rapid progression of HIV dementia even after he abstained from drugs of abuse. It has been shown that remote exposure to neurotoxins may be suf®cient to cause progressive neurodegeneration in humans (Langston e t a l, 1999). Although it is possible that the progression may have been impacted by factors other than drug abuse, for example, viral strains have been associated with neurovirulence (Power e t a l, 1994), other possibilities need to be also considered. While anticonvulsants have also been associated with movement disorders it is a rare idiosyncratic phenomenon, particularly in patients with therapeutic anticonvulsants levels (Harrison e t a l, 1993. However, it is possible that the use of phenytoin and gabapentin in this patient may have unmasked the underlying basal ganglia pathology.
Once the blood brain barrier has been broken down as may occur with cocaine use (Fiala e t a l, 1998) , and HIV infected or activated macrophages enter the brain (B ouwman e t a l, 1998) they may set up positive feed back loops (Nath and Geiger, 1998) that would not require continuous exposure to drugs of abuse. Clinical and experimental studies show that progressive neurological deterioration may continue for days to years even when exposure to neurotoxic substances have been removed (Jones e t a l, 1998; Langston e t a l, 1999; Nath e t a l, 1999) . Hence it is easy to postulate that viral and cellular products released from HIV infected cells may synergize with drugs of abuse such as methamphetamine and cocaine to cause an initial insult to the brain and then cause a domino effec t.
Conclusions
We thus conclude that methamphetamine and cocaine may contribute to the acceleration of HIV dementia and the use of anticonvulsants may unmask an underlying basal ganglia lesion. Careful screening of all patients with HIV infection for drugs of abuse may be necessary. Further studies are needed to determine the extent to which noninjection drug users and recreational drugs users may also be at signi®cant risk of developing HIV dementia and to determine the mechanisms involved in these synergistic interactions.
Materials and methods
Bloo d bra in ba rrie r a ssessme nt
MRIs were performed on a 1.5 T S iemens Magnetom Vision MR system (S iemens Medical S ystems, Iselin, NJ, US A) using a standard, circularly polarized head coil at 3 months prior to, and 3 weeks after the onset of motor symptoms in this patient. Following a standard series of T1 and T2 weighted scans to identify/rule out neurologically signi®cant structural lesions, the time course of post-contrast enhancement was determined in the basal ganglia, to study blood brain barrier integrity.
MRI se q ue nce p a ra m e te rs:
The following sequenc es were used for the standard work up: THK=5 mm, 3% interslice gap, FOV=230 mm, MA=192´256. PD/T2 weighted spin echo (axial): TR/TE1/TE2=2000/20/80 ms, FA=658, FOV=2562 56´180 mm, MA=128´128´90. T1 weighted 3D FLAS H: TR/TE=21/6 ms, FA=308, THK=5 mm, 30% interslice gap, FOV=230 mm, MA=192´256. PD weighted spin echo (axial): TR/TE=2000/14 ms, FA=628, THK=5 mm, 3% interslice gap, FOV= 230 mm, MA=192´256. T1 weighted spin echo (axial, pre-and post-contrast): TR/TE=610/14 ms, FA=628, THK=5 mm, 3% interslice gap, FOV= 230 mm, MA=192´256. Fixed receiver and reconstruction gains.
MRI p o st-c o ntra st p ro to c o l:
Axial T1 weighted spin echo sequence was used to acquire three precontrast image sets, from which mean values were derived. Contrast agent (gadolinium-DTPA; Magnevist [ 0.1 mmol/kg i.v.) was then administered, and post-contrast T1 weighted images using identical acquisition parameters were obtained. Images were collected without interruption (one set everỹ 2 min) for at least 30 min post contrast.
MRI d a ta a na lysis:
For a given region of interest (ROI), the fractional enhancement at time t postcontrast was de®ned as FE(t)=(S (t) Ð S(pre))/S (pre), where S(t) was the mean MRI signal in the ROI at time t post-contrast, and S (pre) was the mean MRI signal in the same ROI prior to contrast administration. Mean FE was determined for the basal ganglia and adjacent white matter as follows: Region-ofinterest (ROI) measurements for each time point pre-and post-contrast were collected using a mask traced to outline basal ganglia structures. These ROI measurements were combined to determine the mean FE in subcortical gray matter. To account for study to study variations in contrast dose, and to assess the contribution of differenc es in rCBV to the post contrast enhancement, these FEs were normalized to the FE in the sagittal sinus at the same time post-contrast. The maximal normalized FE (FEmax), occurring immediately following contrast administration, and the normalized FE 30 min post contrast (FE30), were used as surrogate indices of basal ganglia CBV and blood brain barrier permeability respectively.
